BARDA commits $483m to Moderna for COVID-19 vaccine
According to the agreement, Moderna will use BARDA’s funding to advance its mRNA-1273 vaccine candidate to FDA licensure. The mRNA-1273 is a vaccine candidate against SARS-CoV-2 encoding for
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted authorisation for Moderna’s Spikevax JN.1, an updated Covid-19 vaccine targeting the JN.1 variant of SARS-CoV-2.
FT-4202 is a potent activator of pyruvate kinase-R (PKR) that, in preclinical studies, demonstrated the potential to beneficially impact both anemia and vaso-occlusive crises for people living with
The program will evaluate the safety and efficacy of Intensity’s lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral
“We are thankful to the amazing team at MHRA for the careful and expeditious consideration that led to clearance of our application,” said Dr. Wayne Holman, Co-Founder of Ridgeback